Device Recall Settlements Reach Hundreds of Millions
Device makers selling respiratory products into the US market should weigh recall-related enforcement exposure in their financial planning.
Updated on Nov. 3, 2026 in Healthcare
Live Poll
Do you trust large companies to fix defective products without government pressure?
Dutch medical technology company Philips has reached an agreement in principle with the US Department of Justice to resolve criminal and civil investigations tied to its recall of millions of DreamStation sleep apnoea devices. The company set aside 288 million euros ($322 million) in the third quarter to settle the case, and the settlement remains subject to finalisation of documentation. Healthcare companies that sell respiratory and sleep devices into the US market face the compliance and provisioning consequences illustrated by the case.
Why it matters
The recall followed concerns that users could inhale pieces of noise-cancelling foam from the devices, a safety issue that drove both regulatory exposure and a large financial provision. The settlement's size shows how a product-safety recall can escalate into criminal and civil liability when it becomes a Department of Justice matter.
Philips booked a 288 million euro ($322 million) provision in the third quarter, cutting third-quarter profit to 28 million euros from 187 million euros a year earlier on turnover of 4.4 billion euros, up from 4.3 billion euros. The company maintained its forecast of full-year sales growth between 3.0 and 4.5 percent.
The players
Philips
Amsterdam-headquartered medical technology company whose diagnostic imaging, monitoring and sleep and respiratory care devices are sold to hospitals and patients worldwide.
US Department of Justice
The federal agency that prosecutes criminal and civil violations of US law, including enforcement actions against manufacturers of regulated medical devices.
Roy Jakobs
Chief executive of Philips, who has led the company's turnaround toward profitability after several years of losses.
The details
The agreement in principle resolves previously disclosed criminal and civil investigations connected to the DreamStation recall, which covered millions of sleep apnoea devices. Chief executive Roy Jakobs said the deal was clinched in the last few days, and Philips presented the settlement within its third-quarter results. The provision is booked as a charge against earnings in the quarter, which is why the settlement weighed heavily on reported profit even as turnover held steady.
Timeline
February 2026: Philips posted its first annual profit after three years of losses, with a 897 million euro annual profit gain.
Second quarter 2026: Net profit of 386 million euros was helped by a refund from US tariffs.
Third quarter 2026: Philips set aside 288 million euros to settle the case.
November 3, 2026: Philips announced the agreement in principle with the US Department of Justice.
First quarter 2027: Scheduled payment for the settlement.
Market Landscape
The case shows that a recall of a regulated respiratory device can move from corrective action into a Department of Justice investigation with a multi-hundred-million-euro settlement. Medical device makers selling into the US market operate under this same enforcement exposure, and the provision Philips booked signals how the cost of such matters is now being reflected in earnings.
Operators in medical device supply should treat recall-related legal exposure as a line item that can reach hundreds of millions of euros, and review their own product-safety documentation and reporting procedures accordingly. Companies with US sales should consult qualified counsel on how enforcement risk applies to their specific product lines.
The takeaway
A recall that reaches the Department of Justice can produce a settlement large enough to reshape a quarter's earnings, so product-safety exposure belongs in financial planning. Operators should calendar the expected first-quarter 2027 payment date and track whether the finalised settlement terms change once the documentation is complete.
What happens next
Payment to settle the case is expected in the first quarter of 2027, when the finalised settlement documentation is expected to be completed.
Further reading
For broader context on how device makers manage recall and enforcement exposure, see the Healthcare coverage on this site.
Source note: This article includes information reported by Mail Online.
Live Poll
Do you trust large companies to fix defective products without government pressure?
